Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ:PEPG)

1.865 +0.075 (+4.19%)
Streaming Delayed Price Updated: 1:52 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PepGen Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for PepGen ↗
 
Via Benzinga
News headline image
PepGen: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why This PepGen Analyst Is Bullish On The Biotech Stock ↗
  
Via Benzinga
News headline image
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) 
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827. 
Via Benzinga
News headline image
SAIC, HealthEquity And 3 Stocks To Watch Heading Into Monday ↗
With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
News headline image
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50. 
Via Benzinga
News headline image
Earnings Scheduled For March 23, 2023 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen to Participate in the SVB Securities Global Biopharma Conference
From PepGen Inc.
Via GlobeNewswire
News headline image
Around $12M Bet On This Technology Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
From PepGen Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.